PG
PCRX icon

Pendal Group’s Pacira BioSciences PCRX Stock Holding History

Pendal Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-22,575
Closed -$859K – 490
2019
Q3 		$859K Sell
22,575
-1,799
-7% -$71.8K 0.01% 295
2019
Q2 		$1.06M Buy
24,374
+1,272
+6% +$54K 0.01% 272
2019
Q1 		$879K Hold
23,102
– – 0.01% 313
2018
Q4 		$994K Sell
23,102
-224
-1% -$10.5K 0.02% 268
2018
Q3 		$1.15M Hold
23,326
– – 0.02% 280
2018
Q2 		$748K Buy
23,326
+1,975
+9% +$68.2K 0.01% 336
2018
Q1 		$665K Buy
21,351
+286
+1% +$10.2K 0.01% 359
2017
Q4 		$962K Buy
21,065
+361
+2% +$14.3K 0.01% 306
2017
Q3 		$777K Buy
20,704
+8,196
+66% +$330K 0.01% 344
2017
Q2 		$597K Buy
+12,508
New +$580K 0.01% 347

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Pendal Group's PCRX Position: Q4 2019 in Review

Pendal Group sold out of Pacira BioSciences (PCRX) in Q4 2019, closing a stake of 22,575 shares — an estimated $859K sold.

Pendal Group first reported a position in PCRX in Q2 2017 and held it in 10 quarters. The position peaked at $1.15M in Q3 2018. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

  • Pendal Group reported no remaining Pacira BioSciences position as of Q4 2019 after selling out during the quarter.
  • Pendal Group sold 22,575 Pacira BioSciences shares in Q4 2019, an estimated $859K.
  • Pendal Group first reported a position in Pacira BioSciences in Q2 2017 and held it in 10 quarters.
  • Pendal Group's Pacira BioSciences position peaked at $1.15M in Q3 2018.
  • 231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on Pendal Group's 13F filing for Q4 2019, filed 6 Feb 2020.